The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will compress -29.4% and EPS will wither -76.9%.
The average estimate for revenue is $102.8 million. On the bottom line, the average EPS estimate is $0.12.
Last quarter, ViroPharma recorded revenue of $91.0 million. GAAP reported sales were 36% lower than the prior-year quarter's $143.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS were -$0.07 for Q3 compared to $0.35 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 76.3%, 960 basis points worse than the prior-year quarter. Operating margin was -4.6%, 4,590 basis points worse than the prior-year quarter. Net margin was -5.0%, 2,480 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $427.3 million. The average EPS estimate is $0.70.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,197 members out of 1,238 rating the stock outperform, and 41 members rating it underperform. Among 330 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 321 give ViroPharma a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $31.92.
- Add ViroPharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
A Look Back at Halozyme's Volatile but Rewarding 2013
As 2013 draws to a close, let’s take a look back at Halozyme’s volatile performance throughout the year and review its key collaborations with ViroPharma (Shire), Roche, Baxter, and Pfizer.
3 Surging Biotechs That Made Investors Rich in November
ViroPharma, Idenix, and Geron all boomed in a big way for shareholders over the past month.
3 Humongous Health-Care Stocks This Week
Vanda, Organovo, and Cadence scored the biggest health-care wins this week. But ViroPharma wasn't too far behind.